The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC).
Joyce O'Shaughnessy
Honoraria - Johnson & Johnson
Mario Campone
Consultant or Advisory Role - Novartis; SERVIER
Honoraria - Novartis; SERVIER
Etienne Brain
No relevant relationships to disclose
Patrick Neven
No relevant relationships to disclose
Daniel F. Hayes
Research Funding - Janssen Pharmaceutical
Igor Bondarenko
No relevant relationships to disclose
Thomas W. Griffin
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Jason L. Martin
Employment or Leadership Position - Janssen-Cilag
Stock Ownership - Johnson & Johnson
Peter De Porre
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Janssen Pharmaceutical ; Johnson & Johnson
Thian San Kheoh
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Margaret K. Yu
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Weimin Peng
Employment or Leadership Position - Janssen Research & Development
Stephen R. D. Johnston
No relevant relationships to disclose